FDA’s Draft Guidance on Laboratory-Developed Tests Increases Clinical and Economic Risk to Adoption of Pharmacogenetic Testing

Levy, Kenneth D.Pratt, Victoria M.Skaar, Todd C.Vance, Gail H.Flockhart, David A.2016-02-122016-02-122015-07Levy, K. D., Pratt, V. M., Skaar, T. C., Vance, G. H., & Flockhart, D. A. (2015). FDA's Draft Guidance on Laboratory-Developed Tests Increases Clinical and Economic Risk to Adoption of Pharmacogenetic Testing. Journal of clinical pharmacology, 55(7), 725.https://hdl.handle.net/1805/8303en-USPublisher PolicyUS Food and Drug Administrationlaboratory-developed testspharmacogenetic testingFDA’s Draft Guidance on Laboratory-Developed Tests Increases Clinical and Economic Risk to Adoption of Pharmacogenetic TestingArticle